Test Price
2,800 AED✅ Home Collection Available
BCKDK Gene Genetic Test for Branched-Chain Ketoacid Dehydrogenase Kinase Deficiency in the UAE
Executive Summary & Core Metrics
The BCKDK gene sequencing test employs Next-Generation Sequencing (NGS) technology with 99.9% diagnostic sensitivity to detect pathogenic variants causing branched-chain ketoacid dehydrogenase kinase deficiency. This molecular analysis is conducted under ISO 9001:2015 certified processes at DNA Labs UAE.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary Telephonic Post-Test Interpretation by Genetic Counselors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This genetic test screens the entire coding region and splice sites of the BCKDK gene to identify pathogenic and likely pathogenic variants responsible for branched-chain ketoacid dehydrogenase kinase deficiency. The analysis provides definitive molecular diagnosis for individuals presenting with maple syrup urine disease-like symptoms, enabling targeted dietary management and family carrier screening.
| Feature | Our Test (NGS) | Closest Alternative (Biochemical Enzyme Assay) |
|---|---|---|
| Technology | Next-Generation Sequencing (Illumina platform) | Colorimetric enzyme activity measurement |
| Turnaround Time | 3-4 weeks | 1-2 weeks |
| Analytical Sensitivity | >99.9% for SNVs and small indels | ~90% (may miss partial deficiencies) |
| Sample Requirement | Whole blood, extracted DNA, or dried blood spot (FTA card) | Fresh blood sample (leukocytes) |
| Clinical Value | Identifies causative mutations, carrier status, and family risk | Confirms enzyme dysfunction but does not reveal genetic basis |
Physician Insight & Safety Protocols
"BCKDK deficiency presents a treatable challenge in branched-chain amino acid metabolism. Genetic confirmation through targeted sequencing empowers families and clinicians to implement precise dietary interventions that prevent metabolic decompensation and promote healthy development. I encourage patients to share results with a metabolic specialist for comprehensive management."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Advisory
Never adjust or stop prescribed dietary therapies or medications without consulting your treating metabolic physician. Abrupt changes in branched-chain amino acid intake could precipitate a metabolic crisis requiring urgent medical intervention.
Patient Safety & Exclusion Criteria
- Recent blood transfusion (within 4 weeks) may interfere with germline DNA analysis. Please inform the laboratory if applicable.
- Patients on anticoagulant therapy should notify the phlebotomist before sample collection.
- If you experience vomiting, lethargy, seizures, or abnormal movements, seek emergency medical attention immediately – these may indicate a metabolic crisis.
- This test is not suited for emergency diagnosis; in acute metabolic decompensation, prioritize urgent clinical care.
- All molecular testing adheres to UAE Federal Decree-Law No. 4 of 2016 on Medical Liability for clinical safety standards.
Patient FAQ & Clinical Guidance
1. What is BCKDK deficiency and how does genetic testing help?
BCKDK deficiency is a rare autosomal recessive disorder that impairs the regulation of branched-chain amino acid catabolism. Genetic testing through BCKDK gene sequencing identifies disease-causing mutations, enabling accurate diagnosis, targeted dietary intervention, and reproductive risk counseling for affected families.
2. Who should consider this BCKDK gene sequencing test?
Individuals with clinical features suggestive of maple syrup urine disease, unexplained metabolic acidosis, positive newborn screening results, or a family history of branched-chain amino acid disorders are appropriate candidates. Prenatal testing and carrier screening for at-risk family members are also supported.
3. How accurate is the NGS technology used for this genetic test?
Our NGS platform delivers >99.9% analytical sensitivity and specificity for single nucleotide variants and small insertions/deletions across the BCKDK gene. All clinically significant findings are confirmed by orthogonal Sanger sequencing to ensure diagnostic reliability.
4. What sample types are accepted for this test?
Accepted specimen matrices include peripheral whole blood collected in EDTA tubes, extracted genomic DNA, and dried blood spot cards (FTA). All collections must follow standard venipuncture protocols unless otherwise advised by the laboratory.
5. How will I receive my results and what support is available?
Results are delivered electronically via secure patient portal within 3-4 weeks from sample receipt. A complimentary telephonic consultation with a genetic counselor is provided to interpret findings, discuss clinical implications, and coordinate referral to a metabolic specialist if indicated.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This diagnostic service operates under DHA Facility License Number 1143 and adheres to UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling. Health information governance follows Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical laboratory processes are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and comply with Federal Decree-Law No. 4 of 2016 on Medical Liability for patient safety and consent protocols.
Clinical & Logistical Metadata
| Test Name | BCKDK Gene Sequencing (Branched-Chain Ketoacid Dehydrogenase Kinase Deficiency) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted genomic DNA, or dried blood spot (FTA card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina platform with Sanger confirmation of clinically significant variants |
| ICD-10-CM Code | E71.1 |
| LOINC Code | 92737-7 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians